CNET7h
Considering Collagen Supplements? What You Need to Know About the Benefits and Drawbacks
Collagen supplements are a popular anti-aging tool. Before you take them, here's everything you should know about what ...
New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...
Old newspaper boxes are being used to distribute the overdose reversal drug Narcan
Old newspaper boxes are being repurposed into containers that distribute Narcan, an emergency treatment to reverse drug ...
Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval
Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...
Emerging signs of hope in Long Island's war against fatal overdoses
Narcan, and an ebbing pandemic, have led to a drop in fatal drug overdoses in Nassau and Suffolk, health experts say.
Pet food contamination: These products may contain Listeria or Salmonella
The U.S. Food and Drug Administration (FDA) is advising pet owners to exercise caution and carefully consider what they are ...
US Food and Drug Administration approves 'Dupixent' for treatment of bronchitis
The US Food and Drug Administration FDA has approved French pharmaceutical company Sanofi Dupixent an anti-bronchitis drug ...
KALW19h
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Toxic chemicals found in food packaging: FDA under pressure to take action
Evidence is mounting that food packaging and plastic tableware contain toxic chemicals absorbed by humans, a public health ...
Business Wire23h
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
C&EN9h
The unfulfilled dream of drug reshoring
In October 2019, Janet Woodcock, then the director of the US Food and Drug Administration’s Center for Drug Evaluation and ...
In a Victory for the Free Market, FDA Approves New Schizophrenia Drug
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...